Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NItCHE trial (MITO 33)
2024-516649-38-00Phase 3Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of niraparib and dostarlimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Overall survival. Planned start Dec 2020; status: authorised.
02
Drugs
niraparibdostarlimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-516649-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516649-38-00.